BCM
EUCR

Basso Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Basso Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-43,409
Closed -$430K – 564
2022
Q2 		$430K Hold
43,409
– – 0.05% 361
2022
Q1 		$427K Buy
43,409
+9,600
+28% +$94.2K 0.04% 370
2021
Q4 		$330K Buy
33,809
+615
+2% +$6.03K 0.04% 316
2021
Q3 		$325K Buy
+33,194
New +$324K 0.04% 286

Other funds holding EUCR

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Basso Capital Management's EUCR Position: Q3 2022 in Review

Basso Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2022, closing a stake of 43,409 shares — an estimated $430K sold.

Basso Capital Management first reported a position in EUCR in Q3 2021 and held it in 4 quarters. The position peaked at $430K in Q2 2022. 38 funds tracked by Wall St. Rank hold EUCR as of Q3 2022.

  • Basso Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Basso Capital Management sold 43,409 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2022, an estimated $430K.
  • Basso Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 4 quarters.
  • Basso Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $430K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2022.

Based on Basso Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.